Zimmer once again gives European regulators more time to rule on Biomet deal

Zimmer ($ZMH) agreed to give European regulators more information and time to inspect its planned acquisition of fellow orthopedics company Biomet for $13.35 billion. The European Commission was scheduled to rule on the transaction by March 11. Now the deadline has been extended by a "limited number of days," Zimmer says. This is not the first extension. Originally, a decision was expected by Feb. 16. U.S. regulators must also approve the deal. In spite of the extension for the Europeans, Zimmer still expects the deal to close in the first quarter of 2015. Article (sub. req.)

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.